Encycle Therapeutics
2012
FOUNDED
M&A
STATUS
1-10
EMPLOYEES
M&A
LATEST DEAL TYPE
$80M
LATEST DEAL AMOUNT
Description
Developer of drugs designed to exploit a novel synthetic method to generate drug-like cyclic peptides. The company's drugs are generated by several scaffolds that are membrane permeable and orally bioavailable products, such as nacellins which are ideal for targeting protein-protein interactions, enabling patients to get cured from inflammatory bowel disease and other inflammatory disorders.
Website
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Office
- 101 College Street
- Suite 314
- Toronto, Ontario M5G 1L7
- Canada
+1 (647) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Encycle Therapeutics’s full profile, request a free trial.
Encycle Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 23-Oct-2019 | $80M | 00.000 | 0000 | Completed | Generating Revenue |
| 5. Corporate | 01-Nov-2017 | 00000 | 00.000 | Completed | Generating Revenue | |
| 4. Early Stage VC | 30-Sep-2015 | 00.000 | 00.000 | Completed | Startup | |
| 3. Early Stage VC | 16-Jun-2015 | 00000 | 00.000 | Completed | Startup | |
| 2. Grant | 17-Nov-2014 | $2.5M | Completed | Startup | ||
| 1. Early Stage VC | 11-Nov-2014 | $2.5M | $2.5M | Completed | Startup |
Encycle Therapeutics Competitors (22)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ImmusanT | Venture Capital-Backed | Cambridge, MA | 00 | 000.00 | 00000000000 | 000.00 |
| 000000 00000000000 | Formerly VC-backed | Boston, MA | 00 | 00000 | 00000000 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | Watertown, MA | 00 | 00000 | 000000000 | 00000 |
| 000000 00000000000 | Corporation | Cambridge, MA | 000 | 00000 | 000000 - 000 | 00000 |
| 00000000 000000000 | Venture Capital-Backed | Vienna, Austria | 00.000 | 0000000000 | 00.000 |
Encycle Therapeutics Former Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Accel-Rx | Accelerator/Incubator | Minority | 000 0000 | 000000 0 | ||
| Business Development Bank of Canada | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| CQDM | Government | Minority | 000 0000 | 000000 0 | ||
| MaRS Investment Accelerator Fund | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Merck & Co. | Corporation | 000 0000 | 000000 0 |
Encycle Therapeutics Executive Team (3)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Jeffrey Coull Ph.D | Chief Executive Officer & President |
2 Former Executives
You’re viewing 1 of 3 executives. Get the full list »